share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外國發行人報告
美股SEC公告 ·  08/01 07:08
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market.
RedHill Biopharma Ltd., a specialty biopharmaceutical company, announced on August 1, 2024, the publication of positive Phase 3 study data for RHB-104 in the treatment of Crohn's disease. The study, which included 331 patients and was conducted across over 100 sites globally, demonstrated a 64% increase in efficacy when RHB-104 was added to the standard of care compared to the standard of care alone. The primary endpoint of clinical remission at week 26 was achieved by 36.7% of patients treated with RHB-104 versus 22.4% of those receiving a placebo, with a safety profile similar to placebo. The study's lead investigator, Dr. David Y. Graham, highlighted the potential of RHB-104 as an effective treatment for Crohn's disease, which could serve as an add-on therapy for patients not responding to current treatments. The Crohn's disease market was valued at over $13 billion in 2023. RedHill's CEO, Dror Ben-Asher, expressed the company's commitment to advancing the development of RHB-104 and exploring partnership models to bring this treatment to market.
2024年8月1日，專業生物製藥公司RedHill Biopharma宣佈RHb-104在克羅恩病治療中的三期研究數據發佈取得積極進展。該研究全球100多個地點，包括331名患者，表明相比單純標準治療，加用RHb-104療效增加64％。在第26周的臨床緩解主要終點方面，使用RHb-104治療的患者中有36.7％實現了治療目標，而對照組中僅有22.4％的患者口服安慰劑達到了此目標，安全性大體相仿。該研究的主要負責人Dr. David Y. Graham強調了RHb-104作爲克羅恩病的有效治療方法的潛力，其可作爲對未對現有治療方法產生反應的患者的輔助療法。2023年，克羅恩病市場價值超過130億美元。RedHill的CEO Dror Ben-Asher表示公司致力於推進RHb-104的開發並探索合作模式以將該治療方法推向市場。
2024年8月1日，專業生物製藥公司RedHill Biopharma宣佈RHb-104在克羅恩病治療中的三期研究數據發佈取得積極進展。該研究全球100多個地點，包括331名患者，表明相比單純標準治療，加用RHb-104療效增加64％。在第26周的臨床緩解主要終點方面，使用RHb-104治療的患者中有36.7％實現了治療目標，而對照組中僅有22.4％的患者口服安慰劑達到了此目標，安全性大體相仿。該研究的主要負責人Dr. David Y. Graham強調了RHb-104作爲克羅恩病的有效治療方法的潛力，其可作爲對未對現有治療方法產生反應的患者的輔助療法。2023年，克羅恩病市場價值超過130億美元。RedHill的CEO Dror Ben-Asher表示公司致力於推進RHb-104的開發並探索合作模式以將該治療方法推向市場。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息